The presence of psychiatric comorbidities in patients with chronic obstructive pulmonary disease (COPD) has been linked to increased mortality and decreased functional status. In the present study, we investigated the frequency of anxiety and depression, and the relationships sociodemographic characteristics, pulmonary function test (PFT) parameters, arterial blood gas (ABG) parameters, and the presence of anxiety and depression in COPD patients. Method: Eighty COPD patients were enrolled in the study. The sociodemographic characteristics, treatments, comorbidities, PFT and ABG results of all cases were recorded. The Beck Depression Inventory (BDI) and the Hospital Anxiety Scale (HAS) were used to rate anxiety and depression. Results: Depression was diagnosed in 42 (52.5%) patients according to the BDI scores and 51 (63.8%) patients according to the Hospital Anxiety and Depression Scale -Depression Subscale (HAD-D) scores; anxiety was found in 22 (27.5%) patients according to the Hospital Anxiety and Depression Scale -Anxiety Subscale (HAD-A) scores. When evaluated according to COPD stage, depression and anxiety scores were significantly higher in very severe COPD than in moderate COPD (p<0.01 for BDI, p<0.001 for HAD-D, p<0.001 for HAD-A). Moreover, anxiety scores in severe COPD were significantly higher than in moderate COPD (p<0.01), and in very severe COPD than in severe COPD (p<0.01). Significant negative correlations were found between Beck depression scores and FVC values, between HAD-D scores and FEV 1 , FVC, FEV 1 /FVC values and between HAD-A scores and FEV 1 , FVC, FEV 1 /FVC values. The risk factors for anxiety and depression were found to be living in an urban area and difficulty in falling asleep. Conclusion: We suggest that depressive symptoms are frequently seen in COPD patients and that depression and anxiety can be related to disease stage, disturbances of sleep, and living in an urban area.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) consists of a number of conditions characterized by airway inflammation and destruction of the pulmonary parenchyma. These processes lead to the clinical hallmarks of COPD, which are airflow limitation and dyspnea or shortness of breath 1 . The direct costs of the disease focus primarily on physical rather than psychologic morbidity.
The presence of psychiatric comorbidities in patients with COPD has been linked to increased mortality and decreased functional status 2 . Individuals with COPD have a low health-related quality of life, and anxiety and depression are common comorbidities 3 . Depressed mood has been related to poor health outcomes in COPD patients, with suggestions that depressed mood increases with the disease severity (i.e., Forced Expiratory Volume in 1 second (FEV 1 ) and dyspnea), functional disability, anxiety, and less supportive resources 4 . The prevalence of depression and anxiety vary considerably. This probably reflects the variety of scales and methods used to measure such symptoms. The exact causes of anxiety and depression have not been well defined but several variables have been implicated such as long-term oxygen therapy 5 , percentage of predicted FEV 1 <50%
6 , living alone 6 , female gender 7 , current smoking 8 .
The main objective of this study was to investigate the prevalence of depression and anxiety in COPD patients. We hypothesized that depression and anxiety identified in patients with COPD might be associated with an increased stage of disease. We also aimed to investigate the relationships between presence of depression and anxiety and variable socio-economic factors, pulmonary function tests (PFT), and arterial blood gas (ABG) parameters.
MATERIALS and METHODS
The Ethics Committee of Firat University School of Medicine reviewed and approved the protocol, and all patients signed informed consent after the nature of the study was fully explained prior to their participation.
Selection of Subjects
Subjects for this cross-sectional study were recruited from our outpatient clinic. Eighty stable COPD patients were enrolled into the study. The diagnosis of COPD was made according to the criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Airflow obstruction was defined as a post-bronchodilator FEV 1 /FVC<0.70. The severity of obstruction was also classified according to revised GOLD criteria 9 . The demographic characteristics, duration of symptoms, therapies, comorbidities, and socioeconomical status of all participants were recorded. Medical comorbidities were detected by using a questionnaire. The presence of diabetes mellitus, hypertension, congestive heart failure, ischemic heart disease, malignancy, etc. were recorded. The terms describing the diseases were questioned in a way that was easy to understand-for example, "high blood pressure" was used instead of "hypertension". Patients who had a history of previous psychiatric illness or use of psychiatric drugs and those who were followed in intensive care units for severe respiratory failure were excluded. In addition, the presence of an end-stage disease was accepted as an exclusion criterion.
Spirometry
The pulmonary function tests were performed using a spirometry device ( 9 .
Arterial Blood Gas Measurement
Arterial blood gas samples of all cases were taken from the radial artery at room temperature. Samples were measured by a blood gas analysis device (Rapid lab 348. Biobak., Chiron, Bayer Diagnostic, UK).
The Beck Depression Inventory
The Beck Depression Inventory is a 21-item selfreport inventory used to measure the severity of depression focusing on depressive symptoms, such as hopelessness, irritability, guilt, and feelings of being punished. The Beck Depression Inventory also measures some physical symptoms, such as fatigue, weight loss, and lack of libido. Each item is scored on a 4-point scale of 0 to 3. Results were evaluated as follows; 0-9: no/minimal depression; . Hisli et al. 12 reported the validity and reliability of the Turkish version of BDI 12 , and they determined that the cut-off point for the scale was 17.
The Hospital Anxiety and Depression Scale
Anxiety was assessed at baseline using the Hospital Anxiety and Depression Scale (HADS) 13 . It is a validated screening tool for symptom severity and cases of depression and anxiety in both hospitalized and primary care patients 14 with chronic diseases, including COPD 4, 15 and in the general population 14 . The HADS consists of seven items for depression (HAD-D) and seven items for anxiety (HAD-A). The scores range from 0 to 21 for each subscale, with a score of 0-7 denoting a noncase, 8-10 a possible case, and 11 or higher a probable case 13 . HADS has been standardized for a Turkish population 16 ; the cut-off point for anxiety was found to be 10 and the cut-off point for depression was found to be 7.
Statistical Analysis
The data were analyzed using the statistical package for the social sciences (SPSS) v12.0 software statistical program. Results were presented as group means ± standard deviations (SD). A p value of <0.05 was considered statistically significant. Statistical analysis was performed using the Kruskal-Wallis test for multiple-group comparisons; the MannWhitney U test was performed to test any observed differences for significance and results were interpreted following the Benferroni correction. The Chi-square test was performed to compare gender distribution between groups. Spearman's correlation was used to assess non-parametric data. Binary logistic regression analysis was used to look at confounding factors affecting depression and anxiety scores. Table 2 ). The mean FEV 1 /FVC ratio was significantly higher in female COPD patients compared with male COPD patients who had depression according to the BDI and HAD-D scales (p<0.01 for both). The mean FEV1 levels were significantly higher in female COPD patients who had depression according to the BDI score compared with male COPD patients who had depression (p<0.01) ( Table 3 ). There was a statistically significant increase in the frequency of depression with increasing severity of COPD when evaluated with both the BDI (χ 2 ; 9.609, p=0.008) and the HAD-D (χ 2 ; 16.823, p<0.001) scales. Although there was a trend toward higher anxiety with increasing severity of COPD, no significant difference in the frequency of anxiety between stage II, III and IV COPD was seen (χ 2 ; 2.75, p=0.253) ( Table 4) .
RESULTS

Of
No correlations were observed between arterial blood gas measurements and depression, or anxiety scores. Similary there were no correlations between duration of disease, age, depression, and anxiety scores. Significant mild correlations were found between BDI scores and FVC values (r=-0,227, p<0.05), HAD-D scores and FEV 1 , FVC and FEV 1 / FVC values (r=-0.489, p<0.001; r=-0.462, p<0.001; r=-0.309, p<0.01, respectively) and between HAD-A scores and FEV 1 and FVC, FEV 1 /FVC values (r=-0,395, p<0.001, r=-0,373, p<0.01, r=-0.243, p<0.05, respectively). In addition, there was a positive mild correlation between BDI scores and HAD-D scores, as expected (r= 0.471, p<0.001).
The frequency of use of long-term oxygen therapy was 51.2% (n=41). The rate of comorbidity was 42.5% (n=34), while usage of systemic corticosteroids was 11.2% (n=9) in our study population.
When (Table 5) .
DISCUSSION
The present study found a high prevalence of depression and anxiety among patients with COPD. We determined that living in an urban area was a risk factor for anxiety and that having difficulty falling asleep was a risk factor for depression in COPD patients.
Although two of the most common and leasttreated comorbidities of COPD are anxiety and depression, only a few prospective studies have investigated how to diagnose and manage these disorders and determine their impact on health status among patients with COPD.
The prevalence of depression in patients with COPD has been studied before. Reported prevalence rates range from 6 to 59% 6,17-22 and our findings supported a high frequency of depression in COPD patients. The wide range of prevalence rates could be attributed to several factors: the demographics of the samples, the different instruments used to measure symptoms of depression versus depressive disorders as identified by clinical interviews, and the variation in the cut-off scores of the instruments. Although prevalence rates provide information on the cross-sectional association between COPD and depression, they do not provide crucial information on the temporal relation between COPD and depression.
It remains unclear whether COPD causes a higher risk of depression. There are many mechanisms that could be responsible for the higher risk of depression in patients with COPD. First of all, patients with chronic respiratory disease have worse physical functioning than patients with other chronic diseases, and it has been shown that the level of functional impairment itself is related to a higher rate of depression 23, 24 . Patients with a higher degree of airflow limitation reported more symptoms of depression, and pulmonary function test parameters were found to be a predictor of depression. Patients with severe airway obstruction have previously been shown to face increased risk for depression 6, 20 . In accordance with previous reports, our results showed that there was a statistically significant increase in the frequency of depression with increasing severity of COPD using both the BDI and HAD-D scales. Similar results have been reported by Wagena et al. They showed that the prevalence of depression (assessed using the BDI) in patients with severe or very severe COPD was 37% compared with 22% in patients with mild or moderate COPD but this difference did not reach significance 25 , and they suggested that an insufficient sample size of patients with COPD could be the reason for this result 25 . The lack of control on the course of the disease experienced by the patient could be a second mechanism that results in depressive symptoms 26 . Moreover, the hypoxic nature of severe COPD can result in an organic depression, and dyspnea could lead to much distress and higher depression rates in patients with COPD 27 . In addition, COPD is a disease that primarily occurs in patients of advanced age, and the nature of the disease can result in social isolation, feeling useless, and immobility. These are also factors associated with depression 28 . Previous research has showed an increased prevalence of depression in middle-aged and older adult COPD patients 6, 29 , and a recent study in adults aged 60-70 years old, reported a 1.7-fold higher incidence of depressive symptoms in COPD patients compared to adults without the disease 30 . Few studies have examined depression among the oldest (>70 years) COPD patients, but Ottenheim et al. 31 showed that depressive symptoms and COPD were associated in adults aged 85 years and above. In our study, we found that the depression and anxiety scores were lower in stage II COPD patients, who had the highest mean age compared with stage III and IV COPD. In addition, there was no correlation between age and depression (in both the BDI and HAD-D scores), and anxiety scores. Our results may suggest that age may not be contributing factor to depression and/or anxiety in COPD patients.
COPD is a common disease among the elderly, with a prevalence of 14.2% of individuals over 65 years old, independent of exposure history 32 . It has frequent comorbidity with cardiovascular disease, skeletal muscle dysfunction, osteoporosis, mental illness, and unintentional weight loss 33 . On the other hand, several specific medical conditions are related to an increased risk for mood disorders, and it seems that mood disorders are related to increased morbidity and mortality in patients with specific medical disorders 34 . Some of the studies examining the prevelance of depression in COPD patients have excluded the presence of comorbidity [35] [36] [37] , while others have included comorbidities 38, 39 . Having a comorbid condition was not an exclusion criterion in our study because of the fact that comorbidity is a well-established phenomenon that was found in 42.5% of the patients with COPD in our study. We found that comorbidity was no significant determinant for the level of depression and anxiety in patients with COPD. This result is comparable with the findings of Van den Bernt et al. 30 who compared the risk for physician-diagnosed depression in patients with COPD, patients with diabetes mellitus (DM), and control subjects without chronic conditions. They found that comorbidity did not result in a higher risk for depression in patients with COPD compared to healthy control subjects and DM patients. Similarly, van Manen et al.'s study showed that comorbidity was not responsible for the increased risk of depression in COPD patients 6 . It seems that the increased risk of depression is not the result of having a chronic disease in general, but it is specific for COPD. Schane et al. 29 found that depressive symptoms are significantly more common in patients with COPD than in patients with other chronic illnesses, including coronary heart disease, stroke, hypertension, diabetes, arthritis or cancer. Several factors may contribute to a higher rate of depressive symptoms in COPD when compared to other chronic diseases; COPD is a slowly debilitating disease in which difficulty breathing is a progressive symptom that is distressing to patients 40 . In fact, side effects of bronchodilators can often contribute to increased anxiety, and steroids have several psychiatric side effects 41, 42 . In addition, oxygen therapy can be associated with social stigma 43 . A recently published meta-analysis identified a higher prevalence of depressive symptoms among COPD patients, and meta-regression showed that demographic and clinical factors were not the determinants of heterogeneity in the prevalence of depressive symptoms 44 . Anxiety and depression often appear together in patients with COPD 7 . While the exact causes of these symptoms have not been well defined, several variables have been determined in previous studies 45 . In our study, we could not find any relations between various socioeconomic factors and the presence of depression symptoms. In contrast, Schane et al. 29 showed that independent risk factors for depressive symptoms in COPD patients were younger age, female gender, smoking, single marital status, ≤ high school degree, and co-morbid diagnosis of diabetes, arthritis or cancer. A review of literature related to COPD and depression identified that COPD prevalence was disproportionate in people of different ages, races, socioeconomic status, and geographic locations. Proportionately higher incidences occurred among elderly persons, African Americans, those with a lower socio-economic status, and in developing countries where tobacco was aggressively marketed without regulation 46 . Traditionally, it has been considered that COPD is a disease affecting primarily men. However, recently it has become more prevalent among women than among men 47 . On the other hand, depressive and anxiety disorders are more frequent among women than men in the general population 48 . In some studies, it has been reported that women with COPD reported more psychological distress than men based on self-report measures 8, [49] [50] [51] , although others did not find any relationships between sex and psychological distress 5, 25, 52 . In addition, it has been noted that females with COPD compared to males with COPD had a two fold higher incidence of mood disorders and a one and a half fold higher incidence of anxiety disorders 53, 54 . These findings may be associated with the females' greater psychological distress, worse symptom-related quality of life, and worse perceived control of symptoms 49, 53 . In addition, special symptoms of COPD, particularly dyspnea seems to be more related to psychological condition 49 . Stage et al. did not report any gender differences in psychological distress 52 . As a consequence, the influence of sex differences on the presence of depression and anxiety could not be absolutely detected. Contrary to expectations we did not find any associations between gender and the presence of depression and anxiety. This situation may be accounted for by our small sample size of female patients and the fact that PFT parameters tended to be better in female COPD patients who had depression and anxiety compared with male COPD patients who had depression and anxiety. Possible factors that might affect the presence of depression and anxiety in male and female COPD patients were not questioned in the present study. Therefore, causal inferences cannot be drawn on the direction of the relationship between COPD and psychiatric disorders in men and women. Prospective studies are needed to assess this relationship.
In our study, having difficulty in falling asleep was a risk factor for depression in COPD patients. Because our study is a cross sectional one, we cannot conclude that having difficulty in falling asleep as a risk factor for depression in COPD patients solely based on regression analysis. Moreover sleep disorders are integral parts of both anxiety and depressive disorders. Anxiety and depression are associated with dyspnea, fatigue and altered sleep, all of which also occur in COPD 55 . Sleep disturbances are common and sleep quality is often poor in COPD patients and they are likely to experience anxiety, depression, sleep disturbance, and problems with daily functioning 56, 57 . The causes of nocturnal symptoms and symptomatic sleep disturbance in COPD patients are multiple and include several factors such as age, disease-specific symptoms, presence of comorbid sleep disorders and other medical conditions, depression, impaired quality of life and increased mortality 57 . Further studies are necessary to understand if sleep disturbance is a cause or a result in the depression and/or anxiety in COPD patients.
For the last twenty years, investigators have studied the lifetime prevalence of anxiety or anxiety disorders in patients with respiratory diseases. Lifetime prevalance for anxiety disorders in patients with COPD ranged from 10% to 96% 58, 59 . The anxiety prevalance in our study was 27.5%. Generalized anxiety and panic disorders occurred more frequently in patients with COPD than in the general public 2, 60 . Few studies have investigated the relationships between the magnitude of anxietyrelated symptoms and demographic or anthropometric variables in the COPD population. Greater levels of anxiety in COPD patients have been associated with poor satisfaction with marital relationships 61 , and are more common in women than women and in current smokers than nonsmokers 8 . We evaluated several risk factors (Table 4) for anxiety in COPD patients but we could not show any relations between anxiety scores and these risk factors. Living in an urban area was the only risk factor for anxiety in our study.
We did not assess the sensitivity and specificity of the BDI and HAD-D in patients with COPD, because we did not use any other diagnostic approaches to confirm the presence or absence of anxiety and depression. All analysis in patients with COPD showed that the results of the BDI and HAD-D were compatible with each other (Except stage III and stage IV depression scores). Also we found a significant mild correlation between the BDI and HAD-D scores; therefore, we believe that both depression scales can be used for simple and quick detection of depression in COPD patients.
CONCLUSION
The high rates of depression and anxiety symptoms found in this study raise the issue that clinicians should consider screening COPD patients for depression and anxiety, especially those patients with physical symptoms and functional limitations, since treating depressive symptoms is an important dimension that could improve outcomes in this growing group of patients.
